Tara Dollar, PA
Medical · Grayson, KYNPI 1013461441
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 249 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by GSK at 28.4% of the total.
Across 249 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AbbVie$769
- Lilly USA, LLC$328
- Novo Nordisk$191
- Dexcom, Inc.$175
- Pfizer$133
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,938100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 75 | $1,118 |
| AbbVie | 50 | $769 |
| Lilly USA, LLC | 22 | $328 |
| Novo Nordisk | 10 | $191 |
| Dexcom, Inc. | 12 | $175 |
| Pfizer | 10 | $133 |
| Biohaven Pharmaceuticals, Inc. | 7 | $121 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $118 |
| Merck | 7 | $100 |
| Grifols USA, LLC | 5 | $99 |
| AstraZeneca | 6 | $88 |
| Amgen | 4 | $64 |
| Corcept Therapeutics | 3 | $53 |
| Phathom Pharmaceuticals, Inc. | 3 | $50 |
| Abbott | 3 | $50 |
| Baxter Healthcare | 2 | $47 |
| Boehringer Ingelheim | 3 | $45 |
| Regeneron Healthcare Solutions, Inc. | 2 | $43 |
| Sanofi | 1 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Novartis | 2 | $25 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Harmony Biosciences LLC | 1 | $19 |
| Verona Pharma, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Heartflow, Inc. | 1 | $14 |
| Phadia US Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
How this compares
$3,938 in reported general payments places this provider in the 80th percentile of 222 medical providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $43,719 |
| JardianceEmpagliflozin | 43 | $30,406 |
| JanuviaSitagliptin Phosphate | 30 | $25,204 |
| EliquisApixaban | 26 | $23,510 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $16,959 |
| LinzessLinaclotide | 13 | $14,859 |
| MounjaroTirzepatide | 12 | $12,060 |
| TrulicityDulaglutide | 11 | $10,264 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,357 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $5,974 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 16 | $4,750 |
| Ventolin HfaAlbuterol Sulfate | 39 | $3,768 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 76 | $2,663 |
| Sodium Chloride0.9 % Sodium Chloride | 11 | $1,927 |
| SynthroidLevothyroxine Sodium | 13 | $1,859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $191 | $43,71936 claims |
| Boehringer IngelheimJardiance | $45 | $30,40643 claims |
| MerckJanuvia | $100 | $25,20430 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,118 | $24,31632 claims |
| PfizerEliquis | $133 | $23,51026 claims |
| Lilly USA, LLCMounjaro, Trulicity | $328 | $22,32423 claims |
| AbbVieLinzess, Synthroid | $769 | $16,71826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 222 medical providers in Kentucky.
Other medical in Grayson
- Mikal BaileyPaducah$84K
- Kyle HeraldBowling Green$65K
- Chasity HesterLexington$16K
- Alexandra HuettLouisville$13K
- Danny ThackerFrankfort$11K
- Jessica FrizzellPaducah$10K
- Terry SmithHazard$10K
- Ashley HenegarGeorgetown$10K
- Rachel CrowleyPaducah$8K
- Allison ScottLexington$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.